| Title |
A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China
|
|---|---|
| Published in |
Malaria Journal, April 2018
|
| DOI | 10.1186/s12936-018-2303-8 |
| Pubmed ID | |
| Authors |
Yangmu Huang, Ke Pan, Danlu Peng, Andy Stergachis |
| Abstract |
While China is a major manufacturer of artemisinin and its derivatives, it lags as a global leader in terms of the total export value of anti-malarial drugs as finished pharmaceutical products ready for marketing and use by patients. This may be due to the limited number of World Health Organization (WHO) prequalified anti-malarial drugs from China. Understanding the reasons for the slow progress of WHO prequalification (PQ) in China can help improve the current situation and may lead to greater efforts in malaria eradication by Chinese manufacturers. In-depth interviews were conducted in China between November 2014 and December 2016. A total of 26 key informants from central government agencies, pharmaceutical companies, universities, and research institutes were interviewed, all of which had current or previous experience overseeing or implementing anti-malarial research and development in China. Chinese anti-malarial drugs that lack WHO PQ are mainly exported for use in the African private market. High upfront costs with unpredictable benefits, as well as limited information and limited technical support on WHO PQ, were reported as the main barriers to obtain WHO PQ for anti-malarial drugs by respondents from Chinese pharmaceutical companies. Potential incentives identified by respondents included tax relief, human resource training and consultation, as well as other incentives related to drug approval, such as China's Fast Track Channel. Government support, as well as innovative incentives and collaboration mechanisms are needed for further adoption of WHO PQ for anti-malarial drugs in China. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 22% |
| Student > Master | 4 | 15% |
| Student > Bachelor | 3 | 11% |
| Student > Postgraduate | 3 | 11% |
| Researcher | 2 | 7% |
| Other | 1 | 4% |
| Unknown | 8 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 15% |
| Social Sciences | 4 | 15% |
| Medicine and Dentistry | 3 | 11% |
| Immunology and Microbiology | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 7 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2018.
All research outputs
#15,532,144
of 23,083,773 outputs
Outputs from Malaria Journal
#4,518
of 5,612 outputs
Outputs of similar age
#210,052
of 329,254 outputs
Outputs of similar age from Malaria Journal
#104
of 124 outputs
Altmetric has tracked 23,083,773 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,612 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,254 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.